Dear Colleagues,

Background and History of This Topic: The quest to understand cancer has driven scientific endeavors for over a century. Since the inception of the molecular era of medicine, there has been a fervent push to identify and characterize biomarkers specific to various forms of the disease. Early biomarkers, such as the prostate-specific antigen (PSA) for prostate cancer, revolutionized early detection, and became integral in guiding treatment decisions. Over the years, advancements in genomics, proteomics, metabolomics, and bioinformatics have led to the discovery of a plethora of potential biomarkers, offering finer diagnostic precision, prognosis prediction, and therapeutic response evaluation.

Aim and Scope of the Special Issue: This Special Issue, titled "Novel Biomarkers in the Diagnostics of Cancer", aims to serve as a comprehensive platform for the dissemination of the latest research and advancements in the identification and validation of novel cancer biomarkers. We aim to explore not only the molecular intricacies of these markers but also their clinical applications and potential to shape personalized therapeutic strategies.

Specific areas of focus include, but are not limited to:

• Novel genetic, epigenetic, proteomic, and metabolic markers.
• Technological advancements in biomarker discovery.
• Bioinformatics approaches in data mining for potential biomarkers.
• Clinical utility and validation studies.
• Implications for personalized medicine and therapy adjustments based on biomarker profiles.

Cutting-Edge Research: Emerging research has elucidated the potential of liquid biopsies, capturing circulating tumor DNA, exosomes, and circulating tumor cells as non-invasive diagnostic tools; advanced computational methodologies are being employed to analyze massive datasets to identify potential biomarkers with unprecedented accuracy.

We welcome:

• Original research papers detailing novel findings in the realm of cancer biomarkers.
• Review articles offering comprehensive overviews of specific subfields within cancer biomarker discovery.
• Methodological papers detailing novel techniques or improvements on existing methodologies for biomarker detection or validation.
• Case studies or case series that provide clinical insights into the application of new biomarkers.
• Perspective or opinion pieces discussing challenges, future directions, and ethical considerations in the field.

We intend for this Special Issue to bring together a multidisciplinary cohort of researchers, clinicians, and scholars, shedding light on the future of personalized oncology through the lens of biomarker discovery.

Prof. Dr. Daniela Calina
Dr. Luca Falzone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer biomarkers
• liquid biopsy
• circulating tumor DNA
• exosomes
• cancer personalized medicine
• biomarker validation
• genomic biomarkers
• epigenetic markers
• proteomic signatures
• metabolomic profiling